In our previous study, we revealed that miR‐204 overexpression could sensitize CRC cell to 5‐FU‐based therapy via targeting HMGA2/PI3K signaling;5 however, the miR‐204 expression is abnormally downregulated in CRC tissues. The gene discussed is HMGA2; the disease is colorectal carcinoma.